ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04267939

Recruitment Status : Terminated (There was no anticipated benefit of the experimental combination as tested over available standard therapies; therefore Sponsor has decided to terminate the investigation.)

First Posted : February 13, 2020

Last Update Posted : December 21, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

GlaxoSmithKline

Information provided by (Responsible Party):

Bayer

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	December 1, 2023
Actual Study Completion Date :	December 1, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561.

To Top